Antiviral activity, dose - Response relationship, and safety of entecavir following 24-week oral dosing in nucleoside-naive Japanese adult patients with chronic hepatitis B: A randomized, double-blind, phase II clinical trial

Hepatology International

Volumn 3, Issue 3, 2009, Pages 445-452

  Shindo, Michiko ^a   Chayama, Kazuaki ^b   Mochida, Satoshi ^c   Toyota, Joji ^d   Tomita, Eiichi ^e   Kumada, Hiromitsu ^f   Yokosuka, Osamu ^g   Sata, Michio ^h   Hayashi, Norio ⁱ   Suzuki, Kazuyuki ^j   Okanoue, Takeshi ^k   Tsubouchi, Hirohito ^l   Ishikawa, Hiroki ^m   Seriu, Taku ^m   Omata, Masao ⁿ  

^a Akashi Municipal Hospital   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

^d Sapporo Kosei General Hospital   (Japan)

^e Gifu Municipal Hospital   (Japan)

^f TORANOMON HOSPITAL   (Japan)

^g CHIBA UNIVERSITY   (Japan)

^h KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^j IWATE MEDICAL UNIVERSITY   (Japan)

^k Saiseikai Imperial Gift Foundation Inc Saiseikai Suita Hospital   (Japan)

^l KAGOSHIMA UNIVERSITY   (Japan)

^m BRISTOL MYERS SQUIBB   (United States)

ⁿ UNIVERSITY OF TOKYO   (Japan)

more..

Author keywords

ALT flare; Chronic hepatitis B; Entecavir; HBV DNA; Lamivudine

Indexed keywords

ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; COLON CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; JAPANESE; LIVER CIRRHOSIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; NAUSEA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT DURATION; VIRUS LOAD;

EID: 68949152537     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-009-9135-0     Document Type: Article

References (23)

1. Maddrey WC. Hepatitis B: An important public health issue. J Med Virol 2000;61:362-366. doi: 10.1002/ 1096-9071(200007)61:3<362::AID-JMV14>3.0.CO;2-I
2. Kao JH, Chen DS. The natural history of hepatitis B virus infection. In Lai CL, Locarnini S, editors. Hepatitis B Virus. London: International Medical Press; 2002. 161-172
3. Lok AS, McMahon BJ. American Association for the Study of Liver Diseases (AASLD) practice guidelines. Chronic Hepatitis B. Hepatology 2007;45:507-539. doi: 10.1002/hep.21513
4. Rivkin A. A review of entecavir in the treatment of chronic hepatitis B infection. Curr Med Res Opin 2005;21:1845-1856. doi: 10.1185/ 030079905X65268
5. Wong DKH, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993;119:312-323
6. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998;27:1670-1677. doi: 10.1002/hep.510270628
7. Chang TT, Lai CL, Chien RN, Guan R, Lim SG, Lee CM, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2004;19(11):1276-1282. doi: 10.1111/ j.1440-1746.2004.03428.x
8. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351(15):1521-1531. doi: 10.1056/NEJMoa033364
9. Omata M. Treatment of chronic hepatitis B infection. N Engl J Med 1998;339:114. doi: 10.1056/NEJM199807093390209
10. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2008 update. Hepatol Int 2008;2:263-283. doi: 10.1007/ s12072-008-9080-3
11. Genovesi EV, Lamb L, Medina I, Taylor D, Seifer M, Innaimo S, et al. Efficacy of the carbocyclic 2′-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection. Antimicrob Agents Chemother 1998;42:3209-3217
12. Marion PL, Salazar FH, Winters MA, Colonno RJ. Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication. Antimicrob Agents Chemother 2002;46:82-88. doi: 10.1128/ AAC.46.1.82-88.2002
13. Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, et al. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B. Hepatology 2006;44:1656-1665. doi: 10.1002/hep.21422
14. Ono SK, Kato N, Shiratori Y, Kato J, Goto T, Schinazi RF, et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 2001;107:449-455. doi: 10.1172/JCI11100
15. Lai CL, Rosmawati M, Lao J, Van Vlierberghe H, Anderson FH, Thomas N, et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002;123:1831-1838. doi: 10.1053/gast.2002.37058
16. Chang TT, Gish RG, Hadziyannis SJ, Cianciara J, Rizzetto M, Schiff ER, et al. A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005;129:1198-1209. doi: 10.1053/j.gastro.2005.06.055
17. Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996;24:711-713. doi: 10.1002/hep.510240339
18. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DLJ. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996;24:714-717
19. Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 2004;48:3498-3507. doi: 10.1128/ AAC.48.9.3498-3507.2004
20. Chang TT, Gish R, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1074-1076. doi: 10.1056/NEJMoa051285
21. Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw Y-F, Cianciara J, et al. Entecavir is superior to continued lamivudine for the treatment of lamivudine-refractory. HBeAg-positive chronic hepatitis B. Gastroenterology 2006;130:2039-2049
22. Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998;102:968-975. doi: 10.1172/JCI3731
23. Nair S, Perrillo RP. Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: Is sustained clearance of HBV DNA dependent on levels of pretreatment viremia? Hepatology 2001;34:1021-1026. doi: 10.1053/jhep.2001.28459